Primary research with payers and KOLs supported by landscape assessments to inform trial design, the value proposition, P&R opportunities, and go/no-go decisions.
To position and pricing, life science manufacturers need a clear picture of the likely therapeutic and reimbursement landscape into which they will ultimately launch. This insight is critical to inform planning of Phase 3 trials and supporting evidence generation activities.
4th-Hurdle™ P&R landscape assessments provide a thorough analysis of the current market and the issues that drive decision-making, thus providing the framework for development of a market access strategy that can evolve through product development and as the landscape changes.
- Assessment of the P&R landscape through critical analysis of existing HTA and reimbursement decisions
- Research to determine willingness to pay based on different endpoint scenarios
- Primary research through advisory boards and interviews with payers and clinicians to understand real-world issues and decision drivers, organized by our dedicated Global Advisory Board Group using our proprietary framework Value Based Insurance Design (VBID).